A retrospective study analysing efficacy of Osimertinib EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Osimertinib (Primary) ; Afatinib; Antineoplastics; Erlotinib; Gefitinib; Naquotinib; Olmutinib; Osimertinib; Rociletinib
- Indications Adenocarcinoma; Meningeal carcinomatosis; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 16 Jul 2020 New trial record
- 08 Jul 2020 Results published in the Journal of Thoracic Oncology